Ceva Santé Animale achieved 13.3% growth through €530 in net annual sales during 2011, the first time the company reached the half billion euro mark.
The company also invested record levels in research and development to fund future growth investing over €50m close to 10% of sales. All of Ceva’s geographic zones achieved an increase in operating profit.
Concentration on key brands has continued to drive internal growth where these products now represent more than 60% of sales. Of note was the performance of the Vectra range of external parasiticides distributed exclusively through veterinarians in the US. Ceva’s decision to stay with a “vet only” approach resulted in a 23.2% increase of sales.
Transmune IBD the immune complex vaccine against Gumboro Disease was used to protect more than 16 billion broilers globally against Gumboro disease. Vectormune HVT-NDV the latest in an expanding range of vector vaccines was also launched in several countries, making it possible for the first time to protect against three major diseases in the hatchery.
Ceva re-enforced its position in the strategically important Chinese market following the signature, in July, of a joint venture agreement between Ceva and Huadu creating Beijing Ceva Huadu Biological Co. Ltd, which started operations in January 2012. The Huadu Group has a leading position in China’s poultry vaccine market.
2011 saw a strong contribution from the two newly integrated businesses, Summit VetPharm in the United States and Nature Vet in Australia, both acquired during 2010. Vetech Laboratories, Inc., a Canadian company producing live poultry coccidiosis vaccines was acquired in October giving Ceva access to the vital gut health market in over 40 countries.
Ceva continues to invest massively in its production sites, more than 24m€ in 2011, with notably the June opening of a new poultry vaccine production facility at its Ceva Biomune Campus in Lenexa, Kansas, US.
Commenting on the past year, Dr. Marc Prikazsky, president and CEO of Ceva Santé Animale said, "2011 was a year in which we really began to see the maturation of the Ceva business model. Many major markets presented challenging conditions, highlighting the importance of our earlier decision to invest in the emerging economies where we are now strongly placed."